CLN-049

DRUG2 trials

Sponsors

Cullinan Therapeutics Inc.

Conditions

AML (Acute Myeloid Leukemia)Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RecruitingNCT05143996

Cullinan Therapeutics Inc.Myelodysplastic Syndrome (MDS), Relapsed/Refractory Acute Myeloid Leukemia (AML)

Start: 2021-11-18End: 2027-06-01Target: 60Updated: 2026-01-16

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

Not yet recruitingNCT07722767

Cullinan Therapeutics Inc.AML (Acute Myeloid Leukemia)

Start: 2026-10-15End: 2030-08-31Target: 90Updated: 2026-07-23

Related Papers

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Blood2025-11-03

PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

HemaSphere2023-08-012 citations